Soluble AXL Decoy Protein Inhibits Metastatic Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in addressing tumor invasion and metastasis, particularly as they relate to the AXL and GAS6 pathways, which are critical for metastatic progression and are not effectively targeted by existing therapies.
Innovation Solution
Development of soluble AXL variant polypeptides and antibodies that inhibit AXL and GAS6 pathways, including modified AXL variants with enhanced affinity for GAS6 and specific antibodies binding to GAS6, to treat and prevent tumor invasion and metastasis by blocking AXL signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then general tumor mass can be reduced, but tumor invasion and metastasis are not effectively addressed
Solution Approach 1:
The patent uses soluble AXL protein as an intermediary decoy that binds to GAS6 ligand, preventing GAS6 from activating membrane-bound AXL receptors on tumor cells. This intermediary approach specifically blocks the AXL-GAS6 signaling pathway that drives metastasis without affecting other cancer treatment mechanisms, thereby addressing the unmet need for targeted anti-metastatic therapy
2Reliability
If AXL pathway inhibition is implemented, then metastatic progression is reduced, but potential off-target effects on normal tissue could occur
Solution Approach 1:
The soluble AXL decoy protein selectively intercepts GAS6 ligand in the extracellular space, preventing it from binding to functional AXL receptors on tumor cells. Normal tissues that do not overexpress AXL or GAS6 are spared from this mechanism, providing targeted inhibition with reduced off-target effects compared to systemic chemotherapy
Solution Approach 2:
The patent employs amino acid substitutions in the soluble AXL protein to enhance its binding affinity for GAS6 ligand. This parameter optimization ensures high-specificity binding at therapeutic concentrations, allowing effective pathway inhibition while minimizing the dose required and reducing potential toxicity to normal tissues
3Reliability
If soluble AXL variants with enhanced GAS6 affinity are created, then pathway inhibition is improved, but protein engineering complexity increases
Solution Approach 1:
The patent systematically modifies amino acid residues in the soluble AXL protein structure to enhance GAS6 binding affinity. Specific substitutions in the ligand-binding domain optimize the interaction interface, achieving higher affinity through rational protein engineering rather than trial-and-error approaches
Solution Approach 2:
The soluble AXL protein serves as a simplified copy or mimic of the native membrane-bound AXL receptor, containing only the extracellular ligand-binding domains. This truncated version lacks the transmembrane and intracellular signaling domains, allowing it to function as a safe decoy that binds GAS6 without activating downstream pro-metastatic signaling pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively inhibits metastatic tumor progression by reducing AXL signaling and invasion, demonstrating significant reduction in tumor burden and metastatic lesions without normal tissue toxicity, highlighting AXL as a critical target for metastatic cancer therapy.
Implementation Method 1
soluble AXL variant polypeptides...comprises at least one amino acid modification relative to the wild-type AXL sequence, and wherein said change increases the affinity of the AXL polypeptide binding to GAS6
Implementation Method 2
isolated antibodies or fragments thereof which specifically bind to a GAS6 protein
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3B
AI summary
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.